New Modifier Required on all Single Use Drugs

Why This Topic Matters

The update affects how certain drug claims are documented and reported, which can influence claim processing, compliance review, and audit risk for organizations billing Medicare.

Article Sections

1. Modifier overview and purpose

   Introduces the modifiers discussed in the article and explains the general reporting context for single-dose drug claims.

2. Reasoning for the new JZ modifier

   Summarizes the policy rationale described for adding a new reporting requirement.

3. When the JW and JZ modifier is not used

   Reviews general situations and settings where the modifiers are not applicable.

4. When are the modifiers used?

   Outlines the broad categories of claims and payment contexts discussed in the article.

5. How are these reported on a claim?

   Describes the general claim-line structure used for reporting the drug and the related modifier.

6. Start reporting the new modifier now

   Covers the implementation timeline and phased availability noted in the article.

7. Review timelines

   Summarizes the compliance review milestones and later enforcement dates referenced in the update.

8. When JW and JZ are not used

   Lists the general exception categories discussed for nonuse of the modifiers.

9. When to report JW and JZ modifiers

   Lists the general payment and code categories associated with modifier reporting in the article.

10. Reporting on a claim

    Restates the overall claim-reporting approach in a concise form.

11. Reminder

    Provides a brief closing note that the article is informational and refers readers to the source policy material.